Francisco Monteon, Sudha K Iyengar, Sharon G Adler, Patricia Dickson, Janine LaPage, Rajnish Mehrotra, Kenneth White, Erica L Clinkenbeard, John R Sedor, Anuja Shah, Parag Mehtani, Lili Tong, John A Tayek, Barbara Truitt, Mark D Adams, Cynthia C Nast, Clinton J Miller
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2015;29(12):2235-43
PMID: 25378588
BACKGROUND
Tumoral calcinosis is an autosomal recessive disorder characterized by ectopic calcification and hyperphosphatemia.
METHODS
We describe a family with tumoral calcinosis requiring amputations. The predominant metabolic anomaly identified in three affected family members was hyperphosphatemia. Biochemical and phenotypic analysis of 13 kindred members, together with exome analysis of 6 members, was performed.
RESULTS
We identified a novel Q67K mutation in fibroblast growth factor 23 (FGF23), segregating with a null (deletion) allele on the other FGF23 homologue in three affected members. Affected siblings had high circulating plasma C-terminal FGF23 levels, but undetectable intact FGF23 or N-terminal FGF23, leading to loss of FGF23 function.
CONCLUSIONS
This suggests that in human, as in experimental models, severe prolonged hyperphosphatemia may be sufficient to produce bone differentiation proteins in vascular cells, and vascular calcification severe enough to require amputation. Genetic modifiers may contribute to the phenotypic variation within and between families.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Full Text Sources:
Other Literature Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.